valproate was reduced to 200 mg twice daily even after treatment for three months.
Nocturnal wheezing in children: management with controlledrelease aminophylline Wheezing at night is an appreciable problem for asthmatic children and their parents. The short duration of action of most bronchodilator drugs and the physiological early-morning dip in pulmonary function exacerbate nocturnal symptoms. Although oral theophylline is an effective bronchodilator,l its half life is short and variable,2 so that therapeutic values cannot be maintained while a child sleeps. Use of controlled-release aminophylline in children results in satisfactory serum3 and salivary4 theophylline concentrations eight hours after ingestion, coupled with improvement in respiratory function.5 Controlled-release aminophylline should be of benefit in the management of nocturnal symptoms; a double-blind trial was conducted to determine its efficacy in asthmatic children.
Patients and methods
We studied 25 asthmatic children aged between 5-2 and 15 3 years (mean age 9-3 years). They were chosen because nocturnal symptoms were a major clinical problem. Twenty-two children completed the study satisfactorily, the records of the three others being inadequate. The dosage of aminophylline (mean 11-3 mg/kg) was determined individually for each child with the aid of salivary theophylline assays.4
The study lasted two months: patients were randomly allocated to placebo or controlled-release aminophylline and switched to the alternative preparation after a month. Tablets were taken only at bedtime. Peak flow was recorded on waking (mini Wright peak flow meter). Regular and extra medication was recorded and the early-morning peak flow disregarded if other bronchodilator treatment had been used within six hours. Night symptoms were graded (0-5) and recorded by children or parents, or both, according to a diary card routinely used in our clinic.
Results and comment
The in most responses being "no change." When the morning peak flow results were combined with the parents or the child's assessment of the night then 16 children improved and six showed no change with controlled-release aminophylline compared with placebo (p<005). A non-parametric two-way analysis of variance showed that there was a highly significant increase in the number of good nights when controlled-release aminophylline was being used. We conclude that controlled-release aminophylline is a useful preparation in asthmatic children with noctumal symptoms; no side effects attributable to it were noted in this study.
We thank the children and their parents for their co-operation; Sister Gardner, Mr Smith, and Mr Pugsley for help and advice; Gill Smith for typing the manuscript; and Napp Laboratories for supplying controlledrelease aminophylline (Phyllocontin Continus tablets) and placebo. 
Patients, methods, and results
The effects of nifedipine on an oral glucose tolerance test (100 g of glucose)
were studied in five women and one man. None had evidence of endocrinopathy or were receiving drugs. Mean age was 46 (range 26-55) years. Body weights were within 10 % of the ideal weight. After an initial oral glucose tolerance test 20 mg of nifedipine was administered by mouth eight hourly for three days. A second test was performed two hours after the last dose of nifedipine. The subjects received a diet of 6-7 MJ (1600 kcal) (women) or 8-4 MJ (2000 kcal) (men) (45 % carbohydrate), beginning three days before the first oral glucose tolerance test. Results are expressed as means ± 1 SEM. Differences in the responses before and after nifedipine were assessed by paired Student's t test.
Nifedipine induced distinct glucose intolerance (figure). Fasting plasma glucose concentrations showed a significant increase of 10%; basal insulin concentrations were significantly reduced (26%). During the oral glucose tolerance test plasma glucose concentrations were appreciably raised after administration of the drug, and at 60, 90, and 120 minutes values of 9-56, 9-89, and 7-67 mmol/l respectively were observed (172, 178, and 138 mg/ 100 ml). This contrasted with the normal glucose tolerance in all subjects before administration of nifedipine. In five subjects insulin concentrations were reduced at 30 and 60 minutes; in this subgroup the effect was significant. At 30 minutes the mean insulin concentrations were 0-62±0-12 v 0-85 ±0-14 nmol/l (90+ 18 v 123 +20 uU/ml) (p <0 01); and at 60 minutes 0-76±0-17 v 1-13+0-21 nmol/l (110+24 v 164±30 juU/ml) (p<0 05). In the sixth subject plasma insulin concentration was increased twofold and fourfold at 30 and 60 minutes respectively. This subject was the only one whose plasma glucose concentrations remained normal during the second oral glucose tolerance test. Fasting plasma glucagon concentration was measured by radioimmunoassay (Unger's 30 K antiserum) in three subjects and five additional normal subjects. Glucagon concentrations were significantly increased by nifedipine (0 045 
Comment
The present study shows that in subjects with normal glucose tolerance short-term administration of nifedipine increases fasting plasma glucose concentrations and induces appreciable glucose intolerance associated with a delay of the insulin response. Factors other than impaired insulin release may play a part in the nifedipineinduced glucose intolerance. Particularly relevant are the raised plasma glucagon concentrations that we observed, and the possibility of transient rises in plasma norepinephrine concentrations.2 While we were preparing this paper a study was reported in which the effects of nifedipine (30 mg/day by mouth for 10 days) on carbohydrate metabolism were measured.3 In subjects with normal glucose tolerance raised fasting plasma glucose concentrations were observed; in contrast to our findings, however, an improvement in glucose tolerance, paradoxically associated with a reduced insulin response during the oral glucose tolerance test, was described. In patients with glucose intolerance nifedipine was reported to induce further
